计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S129613-1mg |
1mg |
现货 ![]() |
| |
| S129613-5mg |
5mg |
现货 ![]() |
| |
| S129613-10mg |
10mg |
期货 ![]() |
| |
| S129613-25mg |
25mg |
期货 ![]() |
| |
| S129613-50mg |
50mg |
期货 ![]() |
| |
| S129613-100mg |
100mg |
期货 ![]() |
|
| 英文别名 | AC-30902 | F85017 | HY-50856A | Ruxolitinib S enantiomer | EX-A4005 | 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (betaS)- | ruxolitinib-(S) | CCG-265007 | SCHEMBL99225 | (3s)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]p |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | S-Ruxolitinib (INCB018424) |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | Janus 激酶 1 抑制剂;Janus 激酶 2 抑制剂;Janus 激酶 3 抑制剂;酪氨酸激酶 2 抑制剂 |
| 产品介绍 |
S-Ruxolitinib (INCB018424)是第一个应用到临床的,有效的,选择性JAK1/2抑制剂,IC50为3.3 nM/2.8 nM,作用于JAK1/2比作用于JAK3选择性高130倍以上。 Phase 3。 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770961 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
| INCHI | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m0/s1 |
| InChi Key | HFNKQEVNSGCOJV-HNNXBMFYSA-N |
| Canonical SMILES | C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
| Isomeric SMILES | C1CCC(C1)[C@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
| PubChem CID | 50878566 |
| 分子量 | 306.37 |
| 溶解性 | DMSO 61 mg/mL Water 5 mg/mL Ethanol 61 mg/mL |
|---|---|
| 熔点 | 138-143ºC |
| 分子量 | 306.400 g/mol |
| XLogP3 | 2.100 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 306.159 Da |
| 单同位素质量Monoisotopic Mass | 306.159 Da |
| 拓扑极表面积Topological Polar Surface Area | 83.200 Ų |
| 重原子数Heavy Atom Count | 23 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 453.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| NMR spectrum | Conforms to Structure |
| 1. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA et al.. (2012) Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.. J Med Chem, 55 (22): (10090-107). [PMID:23061660] |
| 2. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.. JCI Insight, 1 (15): (e89790). [PMID:27699253] |
| 3. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L et al.. (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.. Nat Med, 20 (9): (1043-9). [PMID:25129481] |